Sharoon Akhtar

Employment

• Mayo Clinic in Florida Post Doctoral Research Fellow
  2026 - Present
• Mayo Clinic in Florida PhD Researcher
  2020 - 2026
• Mayo Clinic Clinical Research Coordinator
  2020 - 2020
• Mayo Clinic Research Technologist
  2014 - 2020
• Mayo Clinic Special Project Associate
  2012 - 2014

Education

• Mayo Clinic in Florida PhD.
  2020 - 2026
• Forman Christian College MPhil
  2009 - 2011
• Forman Christian College BSc Hon
  2005 - 2009

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• PRSS23 promotes ovarian cancer peritoneal dissemination independent of protease activity
  Journal of Biological Chemistry 2026 DOI: 10.1016/j.jbc.2026.111450
  +Save
• A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression
  Breast Cancer Research 2025 DOI: 10.1186/s13058-025-02117-3
  +Save
• Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia
  Vijay Sagar Madamsetty, Aneel Paulus, Sharoon Akhtar +5 more
  Leukemia & Lymphoma 2020 DOI: 10.1080/10428194.2020.1775204
  +Save
• Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
  Clinical Cancer Research 2019 DOI: 10.1158/1078-0432.ccr-18-3412
  +Save
• Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells
  British Journal of Haematology 2018 DOI: 10.1111/bjh.15515
  +Save
• Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity
  ChemMedChem 2018 DOI: https://doi.org/10.1002/cmdc.201800320
  +Save
• Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
  Blood Cancer Journal 2017 DOI: 10.1038/bcj.2017.40
  +Save
• Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
  Blood Cancer Journal 2016 DOI: 10.1038/bcj.2016.93
  +Save
• The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
  Scientific Reports 2016 DOI: 10.1038/srep26979
  +Save
• Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells
  British Journal of Haematology 2015 DOI: 10.1111/bjh.13304
  +Save
• Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
  PLOS ONE 2015 DOI: 10.1371/journal.pone.0122338
  +Save
• Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
  Blood Cancer Journal 2014 DOI: 10.1038/bcj.2014.74
  +Save
• AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
  British Journal of Haematology 2014 DOI: 10.1111/bjh.12633
  +Save
• In vitro dephytinization and bioavailability of essential minerals in several wheat varieties
  Journal of Cereal Science 2012 DOI: 10.1016/j.jcs.2012.08.017
  +Save